DUBLIN, Sept. 07, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/mhd2t7/global) has announced the addition of the "Global Retinoblastoma Treatment Market 2015-2019" report to their offering.
The global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.
The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma.
The primary aim of twinning programs was to develop retinoblastoma treatment units. It involved collaboration among governments, private sector institutions, and nongovernmental organizations. These initiatives provide better healthcare facilities in terms of primary care, knowledge of diseases, and more effective decision-making for disease treatment.
According to the report, awareness campaigns aimed at parents and healthcare professionals lead to early disease diagnosis and improved survival rates. In Honduras, an awareness campaign for the timely recognition of retinoblastoma yielded positive results in terms of disease diagnosis and treatment.
Further, the report states that the social stigma associated with cancer, fear of removal of the eye, and financial burden are the primary reasons for treatment refusal. Tumor progression to other parts of the body and low survival rate further complicates the situation.
Key vendors
- Baxter
- Bristol-Myers Squibb
- GlaxoSmithKline
- Spectrum Pharmaceuticals
Other prominent vendors
- BioLineRx
- Cellceutix
- Icon Bioscience
- Neotropix
- RXi Pharmaceuticals
- Recombio
For more information visit http://www.researchandmarkets.com/research/mhd2t7/global
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
